Skip to contentpdufa.bio

zelicapavir LOTUS

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

zelicapavir LOTUS is an Enanta Pharmaceuticals Inc program in RSV (pediatric). Its next catalyst is a Readout in Q1 2027.

ENTA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: RSV (pediatric). Sponsor: Enanta Pharmaceuticals Inc (ENTA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027ENTA

Questions

When is zelicapavir LOTUS's next FDA decision or readout?

The next tracked catalyst for zelicapavir LOTUS is a Readout in Q1 2027.

What happened at zelicapavir LOTUS's most recent FDA decision?

No FDA decision for zelicapavir LOTUS is in our archive yet.

What is zelicapavir LOTUS used for?

In our records zelicapavir LOTUS is under review or in development for RSV (pediatric).

Who makes zelicapavir LOTUS?

Enanta Pharmaceuticals Inc (ENTA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.